Rethinking Steroid-Induced Rosacea: Why Vascular Laser Therapy Deserves an Earlier Role

Steroid-induced rosacea (SIR) is traditionally managed through withdrawal of the offending corticosteroid, trigger avoidance, barrier-supportive care, and topical or systemic anti-inflammatory therapy. Although these measures remain essential, persistent erythema, flushing, and telangiectasia may continue to dominate after the acute rebound has stabilized. This editorial argues for earlier vascular assessment and, in selected clinically stabilized patients with a vascular-predominant phenotype, consideration of vascular-directed treatment rather than automatic deferral until prolonged medical-treatment failure. "Earlier" does not mean immediate treatment during an actively inflamed or barrier-compromised phase; it refers to evaluation after the rebound is no longer escalating and superficial vascular features remain prominent. The proposal is device-agnostic at the conceptual level: the FlexSys 577-nm yellow laser (GME German Medical Engineering GmbH, Erlangen, Germany) provides a clinically relevant example, but no vascular device has established universal superiority in SIR. Dermoscopic vascular morphology may assist patient selection, with superficial network-like vessels appearing more responsive than deeper blue venules. Evidence from conventional rosacea and an uncontrolled prospective SIR study provides biological and clinical rationale but does not establish causality, optimal timing, or superiority of any device. The proposal is therefore hypothesis-generating rather than practice-changing. Controlled comparative studies are needed to define patient selection, timing, device matching, safety, patient-reported outcomes, and long-term durability.